A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (NCT01946204)

🧪 Interventions in This Study

• Apalutamide (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (379 Sites)

Showing the first 25 of 379 sites.

• Clinical Research Facility — Birmingham, Alabama
• Clinical Research Facility — Anchorage, Alaska
• Clinical Research Facility — Chandler, Arizona
• Clinical Research Facility — Tucson, Arizona
• Clinical Research Facility — Duarte, California
• Clinical Research Facility — Fullerton, California
• Clinical Research Facility — Laguna Woods, California
• Clinical Research Facility — Los Angeles, California
• Clinical Research Facility — Orange, California
• Clinical Research Facility — Roseville, California
• Clinical Research Facility — Sacramento, California
• Clinical Research Facility — San Bernardino, California
• Clinical Research Facility — San Diego, California
• Clinical Research Facility — San Francisco, California
• Clinical Research Facility — Santa Monica, California
• Clinical Research Facility — Sherman Oaks, California
• Clinical Research Facility — Stanford, California
• Clinical Research Facility — Tarzana, California
• Clinical Research Facility — Torrance, California
• Clinical Research Facility — Denver, Colorado
• Clinical Research Facility — Englewood, Colorado
• Clinical Research Facility — Glenwood Springs, Colorado
• Clinical Research Facility — Grand Junction, Colorado
• Clinical Research Facility — Washington D.C., District of Columbia
• Clinical Research Facility — Aventura, Florida

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Prostatic Neoplasms

• A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer — Phoenix, Arizona
• PSMA PET/CT for Assessment of Recurrent Prostate Cancer — Vancouver, British Columbia
• An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS — Homewood, Alabama
• A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer — Los Angeles, California
• Contributions of a Paramedical Approach in the Prevention and Treatment of Side Effects Associated With Radical Prostatectomy — Fort-de-France,

Explore by condition: All Prostatic Neoplasms clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.